李时珍家方酒品牌怎么样 申请店铺

我要投票 李时珍家方酒在保健酒行业中的票数:74 更新时间:2025-01-08
李时珍家方酒是哪个国家的品牌?     李时珍医药集团位于湖北蕲春,是明代伟大医药学家李时珍的故乡,其丰富而优良的药材资源、独特的自然环境孕育了蕲春古老的中医药文化,为我国重要的药材产地,在当地,素有“路人皆懂医,指草皆为药”之说
李时珍家方酒怎么样

     李时珍医药集团位于湖北蕲春,是明代伟大医药学家李时珍的故乡,其丰富而优良的药材资源、独特的自然环境孕育了蕲春古老的中医药文化,为我国重要的药材产地,在当地,素有“路人皆懂医,指草皆为药”之说。

李时珍医药集团的历史沿于明、清、民国时的李氏酒坊和前店后厂的李时珍药铺(蕲州老街)。1958年4月在蕲州正式挂牌创办李时珍制药厂,生产止咳糖浆等成药共25个品种。1970年8月,开始生产四君子丸、香砂六君丸、六味地黄丸、枸菊地黄丸、归脾丸、黄连素片等。1998年,在李时珍制药厂的基础上整合、并购、组建了李时珍医药集团,使李时珍医药事业得以发扬光大。随着李时珍医药集团有限公司的快速发展,集团目前共有19个中药生产剂型,232个国药准字号产品,4个国家中药保护品种,其中以本草纲目家方酒、麝香祛痛搽剂、香连胶囊等为代表的产品群在全国同类产品中连续多年销量名列前茅。

湖北蕲春本草纲目生物科技园区由李时珍医药集团独家投资建设,园区规划面积2500亩,园内又分为李时珍医药工业园和李时珍本草园等,集GMP药品生产、GAP药材种植、GLP新药科研、GSP医药物流、教学、科普、旅游观光、医疗保健于一体,是华中地区中药现代化生产基地,被称之为“华中药谷”,并被湖北省政府指定为中药实验基地。

集团直接管理全国700多个服务处,营销人员超过9000人,形成“金字塔式”的直营体系。员工在集团有着广泛的发展空间和完善的职业生涯规划,忠诚度和稳定性极高。

自2009年起,集团连续四年上榜中国制药工业百强,2013年荣膺中国制药工业百强第51位。2013年,“本草纲目”品牌被国家工商总局授予驰名保护。

“传时珍医药伟业,谱本草科学新篇”是集团的发展理念,“建百年企业,创世界名牌”是集团的奋斗目标。作为李时珍的衣钵传人,李时珍医药集团弘扬中医药责无旁贷。在传承中医药文化精髓的基础上,用现代化的制药理念和生产技术,对传统中药进行提升改造,用现代化的生产流程和管理方法来生产中药,把传统中药变成现代中药,适应时代发展,满足人民需要。让中医药这一民族瑰宝走向世界,造福人类。


Li Shizhen Pharmaceutical Group, located in Qichun, Hubei Province, is the hometown of Li Shizhen, a great medical scientist in the Ming Dynasty. Its rich and excellent medicinal resources and unique natural environment gave birth to the ancient Chinese medicine culture of Qichun. It is an important origin of medicinal materials in China. In the local area, it is known as "passers-by all know medicine, and the grass is medicine". The history of Li Shizhen Pharmaceutical Group is along the Li's winery in Ming, Qing and the Republic of China and the Li Shizhen pharmacy (Qizhou old street) in QianDian and Houchang. In April 1958, Li Shizhen pharmaceutical factory was officially established in Qizhou, producing 25 kinds of cough syrup and other proprietary drugs. In August 1970, Sijunzi pill, Xiangsha Liujun pill, Liuwei Dihuang pill, Gouju Dihuang pill, Guipi pill and berberine tablet were produced. In 1998, on the basis of Li Shizhen pharmaceutical factory, Li Shizhen Pharmaceutical Group was integrated, merged and established, which made Li Shizhen pharmaceutical enterprise carry forward. With the rapid development of lishizhen Pharmaceutical Group Co., Ltd., the group currently has 19 dosage forms of traditional Chinese medicine production, 232 national pharmaceutical quasi brand products, and 4 national protected varieties of traditional Chinese medicine, among which the product groups represented by compendium of Materia Medica, Shexiang Qutong liniment, Xianglian capsule, etc. have been among the top sales of similar products in the country for many years. Hubei Qichun compendium of Materia Medica Biotechnology Park is exclusively invested and constructed by Li Shizhen Pharmaceutical Group, with a planning area of 2500 mu. The park is also divided into Li Shizhen Pharmaceutical Industrial Park and Li Shizhen materia medica park. It integrates GMP drug production, gap medicine planting, GLP new drug research, GSP medicine logistics, teaching, science popularization, tourism and health care. It is a modern production of traditional Chinese medicine in Central China The base, known as "Chinese Medicine Valley", is designated as the experimental base of traditional Chinese medicine by Hubei provincial government. The group directly manages more than 700 service offices across the country, with more than 9000 marketing personnel, forming a "pyramid style" direct business system. Employees in the group have a wide range of development space and perfect career planning, with high loyalty and stability. Since 2009, the group has been listed in the top 100 of China's pharmaceutical industry for four consecutive years, and won the 51st place in the top 100 of China's pharmaceutical industry in 2013. In 2013, "compendium of Materia Medica" brand was awarded famous protection by the State Administration for Industry and commerce. "Passing on the great achievements of Shizhen medicine, writing a new chapter of science" is the development concept of the group, and "building a century old enterprise, creating a world famous brand" is the goal of the group. As Li Shizhen's successor, Li Shizhen Pharmaceutical Group is responsible for promoting traditional Chinese medicine. On the basis of inheriting the essence of traditional Chinese medicine culture, we should use modern pharmaceutical concept and production technology to upgrade and transform traditional Chinese medicine, use modern production process and management methods to produce traditional Chinese medicine, turn traditional Chinese medicine into modern Chinese medicine, adapt to the development of the times and meet the needs of the people. Let traditional Chinese medicine, a national treasure, go to the world and benefit mankind.

本文链接: https://brand.waitui.com/4b17b5772.html

千城特选小程序码

7×24h 快讯

养殖板块震荡拉升,大湖股份涨停

36氪获悉,截至发稿,养殖板块震荡拉升,大湖股份涨停,国联水产涨超7%,中水渔业、獐子岛、好当家、正邦科技等跟涨。

2小时前

互联网电商板块拉升,凯淳股份涨超15%

36氪获悉,截至发稿,互联网电商板块拉升,凯淳股份涨超15%,青木科技、壹网壹创、星徽股份、狮头股份、三态股份等跟涨。

2小时前

中国煤炭运销协会:焦煤生产将进入阶段性的供应收缩期,供过于求的市场压力有望不再增大

36氪获悉,中国煤炭运销协会1月8日发布炼焦煤市场运行监测旬报称,进入2025年后,煤钢焦产业链运行未有起色,市场各环节对后市信心仍普遍缺乏,对原料采购持谨慎态度,资源冬储意愿不及往年,使得上下游的市场博弈进一步加剧,弱势品种承压较重。从焦煤供需形势看,在安监强化、市场下行的双重压力下,国有大矿利用假期主动控产成为现实,后续焦煤生产将进入阶段性的供应收缩期,供过于求的市场压力有望不再增大。考虑到年初各地积极开工重大项目、“抢出口”效应以及近期房地产市场出现积极变化等因素,钢材后市大概率开启筑底走势,从而支撑焦煤市场以弱稳态势继续运行。

2小时前

冯铖任茅台保健酒业董事长

36氪获悉,天眼查App显示,近日,贵州茅台酒厂(集团)保健酒业有限公司发生工商变更,汪智明卸任法定代表人、董事长,由冯铖接任。贵州茅台酒厂(集团)保健酒业有限公司成立于2005年3月,注册资本26.43亿人民币,由中国贵州茅台酒厂(集团)有限责任公司全资持股。据媒体报道,近日该公司宣布了重要的人事变动,原党委副书记、总经理冯铖升任为公司党委书记、董事长。

2小时前

讯飞星火深度推理模型X1计划将于1月15日正式对外发布

从公司获悉,科大讯飞讯飞星火深度推理模型X1计划将于1月15日正式对外发布。作为当前业界全国产算力平台上唯一的深度推理模型,中文数学对标OpenAI o1,并将在讯飞AI学习机、数学教学助手、医疗等真实场景中率先应用。(证券时报)

2小时前

本页详细列出关于鸿茅药酒的品牌信息,含品牌所属公司介绍,鸿茅药酒所处行业的品牌地位及优势。
咨询